This clinical trial is focused on studying a condition known as Refractory Focal Onset Epilepsy. This type of epilepsy is characterized by seizures that start in one area of the brain and are resistant to treatment with standard medications. The trial will evaluate a new treatment called BHV-7000, which is a prolonged-release tablet designed to be taken orally. The study will compare two different doses of BHV-7000 to a placebo to determine its effectiveness and safety in reducing the frequency of seizures in adults with this condition.

The purpose of the study is to see if BHV-7000 can help reduce the number of seizures experienced by participants. Participants will be randomly assigned to receive either one of the two doses of BHV-7000 or a placebo. The study will last for about 12 weeks, during which participants will take the medication daily and keep a record of their seizures. The goal is to find out if at least half of the participants experience a significant reduction in their seizure frequency.

Throughout the study, the safety and tolerability of BHV-7000 will be closely monitored. Participants will have regular check-ups to assess their health and any side effects they may experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for those with Refractory Focal Onset Epilepsy.